×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Clinical: ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT07392
clinical
1,280 words
KG: ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT07392723)
2026-03-28
section:clinical-trials
kind:clinical-trial
topic:alzheimers
apoe4
omega-3
mci
nutrition
clinical-trial-phase-2
Contents
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT07392723)
Knowledge Graph
Related Hypotheses (20)
Cholesterol-CRISPR Convergence Therapy for Neurodegeneration
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Multi-Modal CRISPR Platform for Simultaneous Editing and Mon
Score: 0.42
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
APOE Isoform Conversion Therapy
Score: 0.44
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.68
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Membrane Cholesterol Gradient Modulators
Score: 0.52
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.48
Extracellular Matrix Stiffness Modulation
Score: 0.43
Piezoelectric Nanochannel BBB Disruption
Score: 0.41
Pharmacological Enhancement of APOE4 Glycosylation
Score: 0.37
Show 15 more
Related Analyses (9)
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Neuroinflammation and microglial priming in early AD
neurodegeneration · completed
Which specific metabolic pathways in APOE4+ microglia are mo
neurodegeneration · completed
How does APOE4's beneficial immune function reconcile with i
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Show 4 more
Related Experiments (12)
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.95
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
ApoE4 Function in Alzheimer's Disease
validation · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood-Based Biomarker Panel for Early AD Detection
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
Multi-omics analysis of myricanol effects on gene expression
exploratory · proposed · Score: 0.88
Show 7 more
See Also (15)
Neurodegeneration
disease · Pages share 10 hypotheses
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 10 hypotheses
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 10 hypotheses
Integrated Stress Response Modulator Therapy in Neurode
therapeutic · Pages share 9 hypotheses
LRP8 (ApoER2) Protein
protein · Pages share 9 hypotheses
ApoER2 Protein
protein · Pages share 9 hypotheses
ApoE (Apolipoprotein E)
protein · Pages share 9 hypotheses
APOE contributes to Alzheimer's disease by regulating b
hypothesis · Pages share 9 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 8 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 8 hypotheses
Therapeutic Modalities in Neurodegeneration
therapeutic · Pages share 8 hypotheses
Trace Amine-Associated Receptor (TAAR) Modulator Therap
therapeutic · Pages share 8 hypotheses
SYK Kinase Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 8 hypotheses
STING Inhibitor Therapy in Neurodegeneration
therapeutic · Pages share 8 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapy for Ne
therapeutic · Pages share 8 hypotheses
Show 10 more
Knowledge Graph (2 edges)
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT07392723)
references
APOE
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT07392723)
references
GFAP